No Data
No Data
Chengda Pharmaceutical (301201.SZ): has cumulatively repurchased 2.10% of its shares.
Gelonghui October 10th | Chengda Pharmaceutical (301201.SZ) announced that as of September 30, 2024, the company has repurchased a total of 3,244,700 shares of the company through a repurchase special securities account in a centralized auction trading manner, accounting for 2.10% of the company's total share capital. The highest fill price was 22.21 yuan/share, the lowest fill price was 14.63 yuan/share, and the total trade amount was 57.0616 million yuan (excluding trading fees).
Subdued Growth No Barrier To ChengDa Pharmaceuticals Co., Ltd. (SZSE:301201) With Shares Advancing 42%
Chengda Pharmaceuticals (301201.SZ): At present, the sales price of the company's L-carnitine products is relatively stable, slightly improved compared to the lowest market conditions.
On September 29, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated during a specific research session that the current sales price of the company's L-carnitine products is relatively stable, showing a slight improvement compared to the lowest market price. There is still some uncertainty about the future price trends of related products.
Chengda Pharmaceutical: 2024 Semi-Annual Report
Chengda Pharmaceutical: 2024 Semi-Annual Report Summary
Chengda Pharmaceutical (301201.SZ): Net income in the first half of the year was 25.1748 million yuan, a year-on-year decrease of 14.23%.
On August 27, Gelonhui reported that the operating income for the first half of 2024 was 0.164 billion yuan, a decrease of 1.55% year-on-year; the net income attributable to the company's shareholders was 25.1748 million yuan, a decrease of 14.23% year-on-year; the net income attributable to the company's shareholders excluding non-recurring gains and losses was 3.164 million yuan, a decrease of 80.18% year-on-year; and the basic earnings per share was 0.1650 yuan.
No Data
No Data